RELATIONSHIP BETWEEN PHARMACOKINETICS AND ANTI-DRUG ANTIBODY STATUS OF ABP 501, A BIOSIMILAR CANDIDATE TO ADALIMUMAB

被引：4
|
作者：
Kaur, P. [1 ]
Chow, V. [1 ]
Zhang, N. [1 ]
Markus, R. [1 ]
机构：
[1] Amgen Inc, Thousand Oaks, CA 91320 USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2015年 / 74卷
关键词：
D O I：
10.1136/annrheumdis-2015-eular.4763
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SAT0167
引用
收藏
页码：714 / 714
页数：1
相关论文
共 50 条
  • [41] IMPACT OF ADALIMUMAB SERUM CONCENTRATION ON EFFICACY AND ASSOCIATION BETWEEN ANTI-DRUG ANTIBODIES AND SERUM CONCENTRATION: 24 WEEK RESULTS FROM A PHASE III STUDY COMPARING SB5 (AN ADALIMUMAB BIOSIMILAR) WITH REFERENCE ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Kay, J.
    Weinblatt, M.
    Keystone, E.
    Genovese, M.
    Ghil, J.
    Cheong, S. Y.
    Hong, E. E.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 136 - 136
  • [42] Infliximab Assay Used in Clinical Practice Validated for Measuring SB2 Infliximab Biosimilar's Serum Drug and Anti-drug Antibody Levels
    Noguier, Guillaume
    Daviere, Simon
    Elouardani, Samia
    Veldet, Can
    Ticaud, Thierry
    Parussini, Ermis
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S398 - S398
  • [43] PROACTIVE MONITORING OF INFLIXIMAB (IFX) AND ADALIMUMAB (ADA) DRUG AND ANTI-DRUG ANTIBODY CONCENTRATION UTILIZING THE LABCORP ASSAY IN INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS
    Perinbasekar, Rajiv A.
    Brown, Sara A.
    Syed, Nauroz
    Lonsako, Shumet
    Cross, Raymond K.
    GASTROENTEROLOGY, 2017, 152 (05) : S392 - S392
  • [44] Relationship Between Patient Sex and Serum Tumor Necrosis Factor Antagonist Drug and Anti-Drug Antibody Concentrations in Inflammatory Bowel Disease; A Nationwide Cohort Study
    Shehab, M.
    Alasfour, H.
    Abdullah, I.
    Alhendi, G.
    Alhadab, A.
    Alfadhli, A.
    Ziyab, A.
    Battat, R.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I249 - I250
  • [45] Relationship Between Patient Sex and Serum Tumor Necrosis Factor Antagonist Drug and Anti-drug Antibody Concentrations in Inflammatory Bowel Disease; A Nationwide Cohort Study
    Shehab, Mohammad
    Alasfour, Hajer
    Abdullah, Israa
    Alhendi, Ghadeer
    Alhadab, Anwar
    Alfadhli, Ahmad
    Ziyab, Ali H.
    Battat, Robert
    FRONTIERS IN MEDICINE, 2021, 8
  • [46] Insulin Receptor Antibody-Iduronate 2-Sulfatase Fusion Protein: Pharmacokinetics, Anti-Drug Antibody, and Safety Pharmacology in Rhesus Monkeys
    Boado, Ruben J.
    Hui, Eric Ka-Wai
    Lu, Jeff Zhiqiang
    Pardridge, William M.
    BIOTECHNOLOGY AND BIOENGINEERING, 2014, 111 (11) : 2317 - 2325
  • [47] Comparison between monotest and traditional batch-based ELISA assays for therapeutic drug monitoring of infliximab and adalimumab levels and anti-drug antibodies
    Moneo, Mikel
    del Agua, Ainhoa Ruiz
    Ruiz-Arguello, Begona
    Rapun, Noelia
    Nagore, Daniel
    El Hamss, Rachid
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2025,
  • [48] The relationship between serum adalimumab and corresponding anti-adalimumab antibody levels: analysis of over 20,000 patient results
    Kelly, Chun
    Imir, Metushi
    Jeanne, Eby
    Stephen, Phagoo
    Morgan, Herle
    James, Iha
    Jane, Yang
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S17 - S18
  • [49] Possibilities and Limitations in Substituting anti-Drug Antibody Titers with Signal-to-Noise Ratios: A Comprehensive Comparison Using Two Clinical Trial Datasets of Adalimumab
    Jang, Dawon
    Kim, Jaeil
    Jo, Youngwon
    Lee, Hyuna
    Go, Ahra
    Kim, Jieun
    Choi, Soyoung
    AAPS JOURNAL, 2024, 27 (01):
  • [50] Clinical Utility of Measuring Infliximab (IFX) and Adalimumab (ADA) and Anti-drug Antibody Levels Using the LabCorp Assay in Patients With Inflammatory Bowel Disease (IBD)
    Brown, Sara
    Perinbasekar, Rajiv
    Syed, Nauroz
    Lonsako, Shumet
    Cross, Raymond
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S406 - S406
12345